Research ExplorerPublicationsLow SARS-CoV-2 infection rates and high vaccine-induced immu...

Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic

Standard

Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. / Brehm, Thomas Theo; Thompson, Michelle; Ullrich, Felix; Schwinge, Dorothee; Addo, Marylyn M; Spier, Anthea; Knobloch, Johannes K; Aepfelbacher, Martin; Lohse, Ansgar W; Lütgehetmann, Marc; Schulze Zur Wiesch, Julian.

In: INT J HYG ENVIR HEAL, Vol. 238, 113851, 09.2021.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Brehm, TT, Thompson, M, Ullrich, F, Schwinge, D, Addo, MM, Spier, A, Knobloch, JK, Aepfelbacher, M, Lohse, AW, Lütgehetmann, M & Schulze Zur Wiesch, J 2021, 'Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic', INT J HYG ENVIR HEAL, vol. 238, 113851. https://doi.org/10.1016/j.ijheh.2021.113851

APA

Brehm, T. T., Thompson, M., Ullrich, F., Schwinge, D., Addo, M. M., Spier, A., Knobloch, J. K., Aepfelbacher, M., Lohse, A. W., Lütgehetmann, M., & Schulze Zur Wiesch, J. (2021). Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. INT J HYG ENVIR HEAL, 238, [113851]. https://doi.org/10.1016/j.ijheh.2021.113851

Vancouver

Brehm TT, Thompson M, Ullrich F, Schwinge D, Addo MM, Spier A et al. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. INT J HYG ENVIR HEAL. 2021 Sep;238. 113851. https://doi.org/10.1016/j.ijheh.2021.113851

Bibtex

@article{65c7ff08dd354b56bcb321295d423bb0,
title = "Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic",
abstract = "In this longitudinal cohort study, we assessed the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) seroconversion rates and analyzed the coronavirus disease 2019 (COVID-19) vaccine-induced immunity of 872 hospital workers at the University Medical Center Hamburg-Eppendorf between May 11 and May 31, 2021. The overall seroprevalence of anti-NC-SARS-CoV-2 antibodies was 4.7% (n = 41), indicating low SARS-CoV-2 infection rates and persistent effectiveness of hospital-wide infection control interventions during the second and third wave of the pandemic. In total, 92.7% (n = 808) out of the entire study cohort, 98.2% (n = 325) of those who had been vaccinated once and all 393 individuals who had been vaccinated twice had detectable anti-S1-RBD-SARS-CoV-2 antibody titers and no significant differences in vaccine-induced immune response were detected between male and female individuals and between different age groups. Vaccinated study participants with detectable anti-NC-SARS-CoV-2 antibody titers (n = 30) developed generally higher anti-S1-RBD-SARS-CoV-2 antibody titers compared to anti-NC-SARS-CoV-2 negative individuals (n = 694) (median titer: 7812 vs. 345 BAU/ml, p < 0.0001). Furthermore, study participants who received heterologous vaccination with AZD1222 followed by an mRNA vaccine showed markedly higher anti-S1-RBD-SARS-CoV-2 antibody titers than individuals who received two doses of an mRNA vaccine or two doses of AZD1222 (median titer: AZD1222/AZD1222: 1069 BAU/ml, mRNA/mRNA: 1388 BAU/ml, AZD1222/mRNA: 9450 BAU/ml; p < 0.0001). Our results indicate that infection control interventions were generally effective in preventing nosocomial transmission of SARS-CoV-2 and that COVID-19 vaccines can elicit strong humoral responses in the majority of a real-world cohort of hospital workers.",
author = "Brehm, {Thomas Theo} and Michelle Thompson and Felix Ullrich and Dorothee Schwinge and Addo, {Marylyn M} and Anthea Spier and Knobloch, {Johannes K} and Martin Aepfelbacher and Lohse, {Ansgar W} and Marc L{\"u}tgehetmann and {Schulze Zur Wiesch}, Julian",
note = "Copyright {\textcopyright} 2021 Elsevier GmbH. All rights reserved.",
year = "2021",
month = sep,
doi = "10.1016/j.ijheh.2021.113851",
language = "English",
volume = "238",
journal = "INT J HYG ENVIR HEAL",
issn = "1438-4639",
publisher = "Urban und Fischer Verlag Jena",

}

RIS

TY - JOUR

T1 - Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic

AU - Brehm, Thomas Theo

AU - Thompson, Michelle

AU - Ullrich, Felix

AU - Schwinge, Dorothee

AU - Addo, Marylyn M

AU - Spier, Anthea

AU - Knobloch, Johannes K

AU - Aepfelbacher, Martin

AU - Lohse, Ansgar W

AU - Lütgehetmann, Marc

AU - Schulze Zur Wiesch, Julian

N1 - Copyright © 2021 Elsevier GmbH. All rights reserved.

PY - 2021/9

Y1 - 2021/9

N2 - In this longitudinal cohort study, we assessed the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) seroconversion rates and analyzed the coronavirus disease 2019 (COVID-19) vaccine-induced immunity of 872 hospital workers at the University Medical Center Hamburg-Eppendorf between May 11 and May 31, 2021. The overall seroprevalence of anti-NC-SARS-CoV-2 antibodies was 4.7% (n = 41), indicating low SARS-CoV-2 infection rates and persistent effectiveness of hospital-wide infection control interventions during the second and third wave of the pandemic. In total, 92.7% (n = 808) out of the entire study cohort, 98.2% (n = 325) of those who had been vaccinated once and all 393 individuals who had been vaccinated twice had detectable anti-S1-RBD-SARS-CoV-2 antibody titers and no significant differences in vaccine-induced immune response were detected between male and female individuals and between different age groups. Vaccinated study participants with detectable anti-NC-SARS-CoV-2 antibody titers (n = 30) developed generally higher anti-S1-RBD-SARS-CoV-2 antibody titers compared to anti-NC-SARS-CoV-2 negative individuals (n = 694) (median titer: 7812 vs. 345 BAU/ml, p < 0.0001). Furthermore, study participants who received heterologous vaccination with AZD1222 followed by an mRNA vaccine showed markedly higher anti-S1-RBD-SARS-CoV-2 antibody titers than individuals who received two doses of an mRNA vaccine or two doses of AZD1222 (median titer: AZD1222/AZD1222: 1069 BAU/ml, mRNA/mRNA: 1388 BAU/ml, AZD1222/mRNA: 9450 BAU/ml; p < 0.0001). Our results indicate that infection control interventions were generally effective in preventing nosocomial transmission of SARS-CoV-2 and that COVID-19 vaccines can elicit strong humoral responses in the majority of a real-world cohort of hospital workers.

AB - In this longitudinal cohort study, we assessed the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) seroconversion rates and analyzed the coronavirus disease 2019 (COVID-19) vaccine-induced immunity of 872 hospital workers at the University Medical Center Hamburg-Eppendorf between May 11 and May 31, 2021. The overall seroprevalence of anti-NC-SARS-CoV-2 antibodies was 4.7% (n = 41), indicating low SARS-CoV-2 infection rates and persistent effectiveness of hospital-wide infection control interventions during the second and third wave of the pandemic. In total, 92.7% (n = 808) out of the entire study cohort, 98.2% (n = 325) of those who had been vaccinated once and all 393 individuals who had been vaccinated twice had detectable anti-S1-RBD-SARS-CoV-2 antibody titers and no significant differences in vaccine-induced immune response were detected between male and female individuals and between different age groups. Vaccinated study participants with detectable anti-NC-SARS-CoV-2 antibody titers (n = 30) developed generally higher anti-S1-RBD-SARS-CoV-2 antibody titers compared to anti-NC-SARS-CoV-2 negative individuals (n = 694) (median titer: 7812 vs. 345 BAU/ml, p < 0.0001). Furthermore, study participants who received heterologous vaccination with AZD1222 followed by an mRNA vaccine showed markedly higher anti-S1-RBD-SARS-CoV-2 antibody titers than individuals who received two doses of an mRNA vaccine or two doses of AZD1222 (median titer: AZD1222/AZD1222: 1069 BAU/ml, mRNA/mRNA: 1388 BAU/ml, AZD1222/mRNA: 9450 BAU/ml; p < 0.0001). Our results indicate that infection control interventions were generally effective in preventing nosocomial transmission of SARS-CoV-2 and that COVID-19 vaccines can elicit strong humoral responses in the majority of a real-world cohort of hospital workers.

U2 - 10.1016/j.ijheh.2021.113851

DO - 10.1016/j.ijheh.2021.113851

M3 - SCORING: Journal article

C2 - 34601375

VL - 238

JO - INT J HYG ENVIR HEAL

JF - INT J HYG ENVIR HEAL

SN - 1438-4639

M1 - 113851

ER -